Last reviewed · How we verify
oral anti-diabetic drug
oral anti-diabetic drug is a SGLT2 inhibitor Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Glucose lowering.
Works by stimulating the release of insulin from the pancreas.
Works by stimulating the release of insulin from the pancreas. Used for Type 2 diabetes.
At a glance
| Generic name | oral anti-diabetic drug |
|---|---|
| Also known as | Glucose lowering |
| Sponsor | Novo Nordisk A/S |
| Drug class | SGLT2 inhibitor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is achieved by binding to the GLP-1 receptor, which increases insulin secretion and decreases glucagon secretion. This results in improved glycemic control and reduced blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Ketoacidosis
Key clinical trials
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
- Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation (PHASE3)
- Effect of Golden Rice-Piper Crocatum Cookies on Neuropathy Prevention in Diabetes (NA)
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (PHASE3)
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral anti-diabetic drug CI brief — competitive landscape report
- oral anti-diabetic drug updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about oral anti-diabetic drug
What is oral anti-diabetic drug?
How does oral anti-diabetic drug work?
What is oral anti-diabetic drug used for?
Who makes oral anti-diabetic drug?
Is oral anti-diabetic drug also known as anything else?
What drug class is oral anti-diabetic drug in?
What development phase is oral anti-diabetic drug in?
What are the side effects of oral anti-diabetic drug?
Related
- Drug class: All SGLT2 inhibitor drugs
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: Glucose lowering
- Compare: oral anti-diabetic drug vs similar drugs
- Pricing: oral anti-diabetic drug cost, discount & access